Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Zhipeng ^a   Liang, Shuang ^a   Lian, Xin ^a   Liu, Lei ^a   Zhao, Shu ^a   Xuan, Qijia ^a   Guo, Li ^a   Liu, Hang ^a   Yang, Yuguang ^a   Dong, Tieying ^a   Liu, Yanchen ^a   Liu, Zhaoliang ^b   Zhang, Qingyuan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Cancer Research Institute Harbin Medial University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GAMMA GLUTAMYLCYCLOTRANSFERASE; GGCT PROTEIN, HUMAN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; IDH1 PROTEIN, HUMAN; IDH2, HUMAN; ISOCITRATE DEHYDROGENASE;

APOPTOSIS; BIOSYNTHESIS; BREAST TUMOR; DRUG EFFECT; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MCF-7 CELL LINE; PATHOLOGY;

APOPTOSIS; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GAMMA-GLUTAMYLCYCLOTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSEPHOSPHATE DEHYDROGENASE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; ISOCITRATE DEHYDROGENASE; MCF-7 CELLS;

EID: 84925881139     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep09301     Document Type: Article

References (59)

1. Simon, S. M. & Schindler, M. Cell biological mechanisms of multidrug resistance in tumors. P NATL ACAD SCI 91, 3497-3504 (1994).
2. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. NAT REVCANCER 2, 48-58; DOI:10.1038/nrc706 (2002).
3. Yang, F., Teves, S. S., Kemp, C. J. & Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics. BBA-REV CANCER 1845, 84-89; DOI:10.1016/j.bbcan.2013.12.002 (2014).
4. Verma, S., Dent, S., Chow, B. J., Rayson, D. & Safra, T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 34, 391-406; DOI:10.1016/j.ctrv.2008.01.008 (2008).
5. Vatsyayan, R. et al. Role of RLIP76 in doxorubicin resistance in lung cancer (Review). Int J Oncol 34, 1505 (2009).
6. Green, A. E. & Rose, P. G. Pegylated liposomal doxorubicin in ovarian cancer. INT J NANOMED 1, 229 (2006).
7. Hui, R. C. et al. Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol. Cancer Ther 7, 670-678; DOI:10.1158/1535-7163 (2008).
8. Harisi, R. et al. Extracellular matrix induces doxorubicin-resistance in human osteosarcoma cells by suppression of p53 function. Cancer biol & ther 6, 1251-1257 (2007).
9. Ferreira, M.-J. U. et al. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells. Anticancer Res 26, 3541-3546 (2006).
10. Song, X. et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene. Cancer Chemoth. Pharm 58, 776-784 (2006).
11. Clynes, M. et al. Recent developments in drug resistance and apoptosis research. Crit Rev Oncol Hematol 28, 181-205 (1998).
12. van der Kolk, D. M. et al. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res 4, 1727-1736 (1998).
13. Skovsgaard, T., Nielsen, D., Maare, C. & Wassermann, K. Cellular resistance to cancer chemotherapy. Int Rev Cytol 156, 77-157 (1994).
14. Noguchi, M. et al. Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells. Glycobiology 16, 641-650; DOI:10.1093/glycob/cwj103 (2006).
15. Chuthapisith, S., Layfield, R., Kerr, I. D., Hughes, C. & Eremin, O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int J Oncol 30, 1545-1551 (2007).
16. Aebersold, R. & Mann, M. Mass spectrometry-based proteomics. Nature 422, 198-207; DOI:10.1038/nature01511 (2003).
17. Yates Iii, J. R., Gilchrist, A., Howell, K. E. & Bergeron, J. J. Proteomics of organelles and large cellular structures. Nat Rev Mol Cell Bio 6, 702-714; DOI:10.1038/nrm1711 (2005).
18. Walther, T. C. & Mann, M. Mass spectrometry-based proteomics in cell biology. J cell biol 190, 491-500; DOI:10.1083/jcb.201004052 (2010).
19. Michalski, A. et al. Mass spectrometry-based proteomics using Q Exactive, a high-performance benchtop quadrupole Orbitrap mass spectrometer. Mol Cell Proteomics 10, M111. 011015; DOI:10.1074/mcp.M111.011015 (2011).
20. Olsen, J. V. et al. Higher-energy C-trap dissociation for peptide modification analysis. Nat. Methods 4, 709-712; DOI:10.1038/nmeth1060 (2007).
21. Nagarajuna, N. et al. Systems-wide perturbation analysis with near complete coverage of the yeast proteome by single-shot UHPLC runs on a bench-top Orbitrap. Mol. Cell. Proteomics 11, M111; DOI:10.1074/mcp.M111.013722 (2011).
22. Raso, C. et al. Characterization of breast cancer interstitial fluids by TmT labeling, LTQ-Orbitrap Velos mass spectrometry, and pathway analysis. J proteome res 11, 3199-3210; DOI:10.1021/pr2012347 (2012).
23. Weinkauf, M. et al. 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma. Electrophoresis 30, 974-986; DOI:10.1002/elps.200800508 (2009).
24. Di Iorio, B., Guastaferro, P. & Bellizzi, V. Relationship between resistance to erythropoietin and high anomalous hemoglobin levels in hemodialysis patients with beta-thalassemia minor. Blood Purif 21, 376-380 (2003).
25. Di Iorio, B. R., Guastaferro, P., Cillo, N., Cucciniello, E. & Bellizzi, V. Long-term L-carnitine administration reduces erythropoietin resistance in chronic hemodialysis patients with thalassemia minor. Drug Target Insights 2, 1-7 (2007).
26. Wen, Q. et al. Proteomic profiling identifies haptoglobin as a potential serum biomarker for steroid-resistant nephrotic syndrome. AMJNEPHROL 36, 105-13; DOI:10.1159/000339755 (2012).
27. Zhou, C. et al. Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 10, R105; DOI:10.1186/bcr2210 (2008).
28. Yu, S., Meng, Q., Hu, H. & Zhang, M. Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer. Int J Clin Exp Pathol 7, 5538-5548 (2014).
29. Koumangoye, R. B. et al. Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. Mol Cancer 12, 167; DOI:10.1186/1476-4598-12-167 (2013).
30. Tortora, G. et al. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat 10, 81-100; DOI:10.1016/j.drup.2007.03.003 (2007).
31. Ruppen, I. et al. Differential protein expression profiling by iTRAQ-two-dimensional LC-MS/MS of human bladder cancer EJ138 cells transfected with the metastasis suppressor KiSS-1 gene. Mol Cell Proteomics 9, 2276-2291; DOI:10.1074/mcp.M900255-MCP200 (2010).
32. Kuo, M. T. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities. ANTIOXID REDOX SIGN 11, 99-133; DOI:10.1089/ars.2008.2095 (2009).
33. Manuela, P. et al. Modulation of doxorubicin resistance by the glucose-6-phosphate dehydrogenase activity. Biochem J 439, 141-149; DOI:10.1042/BJ20102016 (2011).
34. Amano, T. et al. Widespread Expression of γ-Glutamyl Cyclotransferase Suggests It Is Not a General Tumor Marker. J Histochem Cytochem 60, 76-86; DOI:10.1369/0022155411428468 (2012).
35. Kageyama, S. et al. A novel tumor-related protein, C7orf24, identified by proteome differential display of bladder urothelial carcinoma. PROTEOMICS-Clinical Applications 1, 192-199; DOI:10.1002/prca.200600468 (2007).
36. Gromov, P. et al. Proteomic profiling of mammary carcinomas identifies C7orf24, a γ-glutamyl cyclotransferase, as a potential cancer biomarker. J proteome res 9, 3941-3953; DOI:10.1021/pr100160u (2010).
37. Uejima, D. et al. Involvement of cancer biomarker C7orf24 in the growth of human osteosarcoma. Anticancer Res 31, 1297-1305 (2011).
38. Meister, A. & Anderson, M. E. Glutathione. Annu Rev Biochem 52, 711-760; DOI:10.1146/annurev.bi.52.070183.003431 (1983).
39. Oakley, A. J. et al. The Identification and Structural Characterization of C7orf24 as γ-Glutamyl Cyclotransferase AN ESSENTIAL ENZYME IN THE γ-GLUTAMYL CYCLE. J Biol Chem 283, 22031-22042; DOI:10.1074/jbc.M803623200 (2008).
40. Gehrmann, M. L., Fenselau, C. & Hathout, Y. Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J proteome res 3, 403-409 (2004).
41. Rakheja, D., Konoplev, S., Medeiros, L. J. & Chen, W. IDH mutations in acute myeloid leukemia. Hum Pathol 43, 1541-1551; DOI:10.1016/j.humpath.2012.05.003 (2012).
42. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274; DOI:10.1126/science.1133427 (2006).
43. Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812; DOI:10.1126/science.1164382 (2008).
44. Mardis, E. R. et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361, 1058-1066; DOI:10.1056/NEJMoa0903840 (2009).
45. Sau, A., Pellizzari Tregno, F., Valentino, F., Federici, G. & Caccuri, A. M. Glutathione transferases and development of new principles to overcome drug resistance. Arch Biochem Biophys 500, 116-122; DOI:10.1016/j.abb.2010.05.012 (2010).
46. Dirven, H. A., van Ommen, B. & van Bladeren, P. J. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 9, 351-360; DOI:10.1021/tx950066l (1996).
47. Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anticancer drug resistance. Oncogene 22, 7369-7375; DOI:10.1038/sj.onc.1206940 (2003).
48. Peluso, S. & Chiappetta, G. High-mobility group A (HMGA) proteins and breast cancer. Breast Care 5, 81-85; DOI:10.1159/000297717 (2010).
49. D'Angelo, D. et al. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer 14, 851; DOI:10.1186/1471-2407-14-851 (2014).
50. Dennison, J. B. et al. Lactate Dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 19, 3703-3713; DOI:10.1158/1078-0432.CCR-13-0623 (2013).
51. Paul, C. et al. Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). Exp Cell Res 316, 1535-1552; DOI:10.1016/j.yexcr.2010.03.006 (2010).
52. Kanagasabai, R., Krishnamurthy, K., Druhan, L. J. & Ilangovan, G. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. J Biol Chem 286, 33289-33300; DOI:10.1074/jbc.M111.249102 (2011).
53. Cayado-Gutié rrez, N. et al. Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN. Cell Stress Chaperones 18, 243-249; DOI:10.1007/s12192-012-0367-x (2013).
54. Musiani, D. et al. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy. FASEB J 28, 4055-4067 (2014).
55. Vander Borght, S. et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 28, 1370-1380; DOI:10.1111/j.1478-3231.2008.01889.x (2008).
56. Chen, H., Hao, J., Wang, L. & Li, Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101, 432-440; DOI:10.1038/sj.bjc.6605185 (2009).
57. Coppola, A. et al. In vitro phenotypic, genomic and proteomic characterization of a cytokine-resistant murine beta-TC3 cell line. PLoS One 7, e32109; DOI:10.1371/journal.pone.0032109 (2012).
58. Rhrissorrakrai, K. & Gunsalus, K. C. MINE: Module Identification in Networks. BMC Bioinformatics 12, 192; DOI:10.1186/1471-2105-12-192 (2011).
59. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498-2504; DOI:10.1101/gr.1239303 (2003).